Updated:
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a other based in Foster City, founded 2018; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
Mirum Pharmaceuticals
Mirum develops patient-inspired therapies for rare disease, advancing medicines where unmet need is greatest. Mirum is relentlessly rare. Learn more.
General information
Firm type
other
Year founded
2018
Location
Region
North America
Country
United States
City
Foster City
Corporate office
Foster City, CA, United States
Additional offices
Zug, Switzerland
Sector focus
Frequently asked questions
Who runs investment decisions at Mirum Pharmaceuticals?
Mirum Pharmaceuticals is a publicly traded biopharmaceutical company, not a family office or investment firm. Investment decisions are made by its executive leadership and board of directors, whose names are not disclosed in public sources accessible for this profile.
How does Mirum Pharmaceuticals source proprietary deal flow?
Mirum develops its pipeline internally and through business development. The company began with an in-licensed program that had been deprioritized by a larger organization, and has since built a portfolio of three approved medicines and clinical programs targeting rare liver diseases (per the firm, accessed June 2025).
Does Mirum Pharmaceuticals participate in fund commitments or only direct deals?
Mirum Pharmaceuticals does not make fund commitments or direct investments as a financial firm. It conducts research, development, and commercialization of therapies for rare diseases.
What investment stages does Mirum Pharmaceuticals typically target?
Mirum focuses on drug development from early-stage clinical trials through regulatory approval and commercialization. Its pipeline includes programs in various stages, from preclinical to approved therapies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: